Xynomic Pharmaceuticals (XYNO) Stock Price, News & Analysis

Company Overview

Xynomic Pharmaceuticals (OTCMKTS:XYNO) is a clinical-stage biopharmaceutical company headquartered in China that focuses on the research, development, manufacturing and commercialization of innovative small-molecule drugs. The company’s pipeline spans oncology and anti-infective therapies, with multiple candidates in various stages of preclinical and clinical evaluation. Xynomic leverages proprietary discovery platforms and collaborates with academic institutions and contract research organizations to advance its drug candidates toward regulatory approval both domestically and internationally.

The company’s principal activities include target identification, medicinal chemistry optimization, formulation development and large-scale manufacturing. Xynomic operates research laboratories and pilot-scale production facilities in Suzhou New District, where it conducts compound screening, toxicology studies and process validation. In addition to its in-house efforts, Xynomic has established partnerships to support clinical trials and out-license select assets to strategic collaborators in regions such as North America and Europe.

Founded by a team of experienced pharmaceutical scientists and executives, Xynomic has grown through a combination of internal R&D and selective acquisitions of development-stage assets. The company’s management team brings expertise in regulatory affairs, clinical operations and commercial strategy, reflecting a focus on transforming early-stage innovation into marketable therapies. While primarily serving the Chinese market, Xynomic continues to pursue global registration pathways for its lead candidates, positioning itself as an emerging player in the international biotech arena.

Key Stats

• Today's Range: $2.22 to $2.22
• 50-Day Range: $2.22 to $2.22
• 52-Week Range: $0.20 to $3.84
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XYNO Stock Analysis - Frequently Asked Questions

How have XYNO shares performed this year?

Xynomic Pharmaceuticals' stock was trading at $2.22 at the beginning of 2025. Since then, XYNO stock has increased by 0.0% and is now trading at $2.22.

How do I buy shares of Xynomic Pharmaceuticals?

Shares of XYNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:XYNO
• CIK: N/A
• Web: xynomicpharma.com
• Phone: 86 21 5418 0212
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A